Adaptive trials are being used in the BAN2401 trial, Dominantly Inherited Alzheimer Network–Treatment Unit [41], European Prevention of Alzheimer Disease initiative [42], and the Intranasal Oxytocin for Fronto-temporal Dementia (FOXY) trial of intranasal oxytocin for frontotemporal dementia [43]. This evidence concerns the gene OXT and early-onset autosomal dominant Alzheimer disease.